Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387014386> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4387014386 endingPage "AB83" @default.
- W4387014386 startingPage "AB83" @default.
- W4387014386 abstract "Patients with moderate–severe atopic dermatitis (msAD) often experience chronic cycles of pruritus and scratching, affecting sleep and quality-of-life. Rocatinlimab, a monoclonal antibody that targets OX40, is being evaluated for the treatment of msAD. We evaluated the effects of rocatinlimab on patient- reported outcomes (PROs) in adult patients with msAD. This Phase 2b, multicenter, double-blind, placebo-controlled trial, randomly assigned adult patients to subcutaneous rocatinlimab every 4 weeks (Q4W; 150 or 600mg) or every 2 weeks (300 or 600mg) or placebo, for 18 weeks, followed by an 18 week active treatment extension and a 20-week off-treatment follow-up (Week 56). PROs included pruritus and sleep disturbance (SD) scores, measured using a Numerical Rating Scale (NRS), and the Dermatology Life Quality Index (DLQI). These were assessed at baseline to Week 16 and until Week 56. Overall, 267 patients were randomized (rocatinlimab: n=210; placebo: n=57). From baseline to Week 16, percentage reductions in NRS-pruritus (p≤0.029) and NRS-SD scores (p≤0.025) were greater in the rocatinlimab groups compared with placebo. Improvement in pruritus and SD scores in the rocatinlimab groups was maintained until Week 56. Greater reductions in DLQI scores, indicative of improved health- related quality-of-life, in the rocatinlimab groups compared with placebo up to Week 16 (all p<0.05) were observed; scores continued to improve in the rocatinlimab groups to Week 36 and were maintained during the off-treatment period. Rocatinlimab showed significant improvements in PROs in patients with msAD, which were maintained up to Week 56 (despite being off treatment for 20 weeks) suggestive of potential disease modifying effects." @default.
- W4387014386 created "2023-09-26" @default.
- W4387014386 creator A5015905197 @default.
- W4387014386 creator A5052402905 @default.
- W4387014386 creator A5081579877 @default.
- W4387014386 creator A5088512165 @default.
- W4387014386 date "2023-09-01" @default.
- W4387014386 modified "2023-09-26" @default.
- W4387014386 title "42942 Rocatinlimab demonstrates improvements in patient-reported outcomes in adult patients with moderate–severe atopic dermatitis in a Phase 2 trial" @default.
- W4387014386 doi "https://doi.org/10.1016/j.jaad.2023.07.337" @default.
- W4387014386 hasPublicationYear "2023" @default.
- W4387014386 type Work @default.
- W4387014386 citedByCount "0" @default.
- W4387014386 crossrefType "journal-article" @default.
- W4387014386 hasAuthorship W4387014386A5015905197 @default.
- W4387014386 hasAuthorship W4387014386A5052402905 @default.
- W4387014386 hasAuthorship W4387014386A5081579877 @default.
- W4387014386 hasAuthorship W4387014386A5088512165 @default.
- W4387014386 hasConcept C126322002 @default.
- W4387014386 hasConcept C141071460 @default.
- W4387014386 hasConcept C142724271 @default.
- W4387014386 hasConcept C159110408 @default.
- W4387014386 hasConcept C16005928 @default.
- W4387014386 hasConcept C168563851 @default.
- W4387014386 hasConcept C204787440 @default.
- W4387014386 hasConcept C27081682 @default.
- W4387014386 hasConcept C2776173921 @default.
- W4387014386 hasConcept C2778329239 @default.
- W4387014386 hasConcept C2779134260 @default.
- W4387014386 hasConcept C2779951463 @default.
- W4387014386 hasConcept C2780699399 @default.
- W4387014386 hasConcept C71924100 @default.
- W4387014386 hasConceptScore W4387014386C126322002 @default.
- W4387014386 hasConceptScore W4387014386C141071460 @default.
- W4387014386 hasConceptScore W4387014386C142724271 @default.
- W4387014386 hasConceptScore W4387014386C159110408 @default.
- W4387014386 hasConceptScore W4387014386C16005928 @default.
- W4387014386 hasConceptScore W4387014386C168563851 @default.
- W4387014386 hasConceptScore W4387014386C204787440 @default.
- W4387014386 hasConceptScore W4387014386C27081682 @default.
- W4387014386 hasConceptScore W4387014386C2776173921 @default.
- W4387014386 hasConceptScore W4387014386C2778329239 @default.
- W4387014386 hasConceptScore W4387014386C2779134260 @default.
- W4387014386 hasConceptScore W4387014386C2779951463 @default.
- W4387014386 hasConceptScore W4387014386C2780699399 @default.
- W4387014386 hasConceptScore W4387014386C71924100 @default.
- W4387014386 hasIssue "3" @default.
- W4387014386 hasLocation W43870143861 @default.
- W4387014386 hasOpenAccess W4387014386 @default.
- W4387014386 hasPrimaryLocation W43870143861 @default.
- W4387014386 hasRelatedWork W2771084125 @default.
- W4387014386 hasRelatedWork W2884557367 @default.
- W4387014386 hasRelatedWork W3158030853 @default.
- W4387014386 hasRelatedWork W3206152140 @default.
- W4387014386 hasRelatedWork W3210501554 @default.
- W4387014386 hasRelatedWork W3211634059 @default.
- W4387014386 hasRelatedWork W4295338524 @default.
- W4387014386 hasRelatedWork W4309095504 @default.
- W4387014386 hasRelatedWork W4318069789 @default.
- W4387014386 hasRelatedWork W4366171132 @default.
- W4387014386 hasVolume "89" @default.
- W4387014386 isParatext "false" @default.
- W4387014386 isRetracted "false" @default.
- W4387014386 workType "article" @default.